logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
M

Mustafa Özgüroğlu

istanbul university - cerrahpasa

61H-index
548Paper Count
4.2WCitation Count
Published Papers 100
Publication Date
logo
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study
errEuropean Urology Oncology
IF9.3
err2025-11-17
err0
errOAAI
errAndrew J. Armstrong; Fred Saad; Mototsugu Oya; Karina Vianna; Mustafa Özgüroğlu; Craig Gedye; Gary L. Buchschacher; Ji Youl Lee; Urban Emmenegger; Jiří Navrátil; Juan Antonio Virizuela; Anibal Salazar; Denis Maillet; Hiroji Uemura; Christian Hosius; David McGuinness; Arnold Degboe; Noel Clarke
errShare
errSave
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
errNature Medicine
IF50
err2025-10-07
err0
errOAAI
errGerhardt Attard; Neeraj Agarwal; Julie N. Graff; Shahneen Sandhu; Eleni Efstathiou; Mustafa Özgüroğlu; Andrea J. Pereira de Santana Gomes; Karina Vianna; Hong Luo; Geoffrey T. Gotto; Heather H. Cheng; Won Kim; Carly R. Varela; Daneen Schaeffer; Kassie Kramer; Susan Li; Benoit Baron; Fei Shen; Suneel D. Mundle; Sharon A. McCarthy; David Olmos; Kim N. Chi; Dana E. Rathkopf
errShare
errSave
Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: outcomes in age, sex, and platinum subgroups from the phase 3 CASPIAN study
errClinical Lung Cancer
IF3.3
err2025-08-05
err0
errOAAI
errNiels Reinmuth; Jonathan W. Goldman; Yuanbin Chen; Katsuyuki Hotta; Dmytro Trukhin; Galina Statsenko; Maximilian Hochmair; Mustafa Özgüroğlu; Jun Ho Ji; Marina Chiara Garassino; Artem Poltoratskiy; Francesco Verderame; Libor Havel; Igor Bondarenko; György Losonczy; Nikolay Conev; Shannon Kummer; Helen Mann; Priti Chugh; Tapashi Dalvi; Luis Paz-Ares
errShare
errSave
The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium
errONCOLOGIST
IF4.2
err2025-07-01
err0
PREAI
errCamoz, Elif Sertesen; Bolek, Hatice; Kuzu, Omer Faruk; Sim, Saadet; Karakas, Hilal; Sekmek, Serhat; Guliyev, Murad; Akkus, Aysun Fatma; Isik, Selver; Tural, Deniz; Arslan, Cagatay; Goksu, Sema Sezgin; Sever, Ozlem Nuray; Karadurmus, Nuri; Karacin, Cengiz; Ozguroglu, Mustafa; Sendur, Mehmet Ali Nahit; Yekeduz, Emre; Urun, Yuksel
errShare
errSave
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study☆
errAnnals of Oncology
IF65.4
err2025-05-16
err0
PREAI
errC. Gratzke; M. Özgüroğlu; A. Peer; M.A.N. Sendur; M. Retz; J.C. Goh; W. Loidl; G. Jayram; S.-S. Byun; C. Kwak; M. Kwiatkowski; R. Manneh Kopp; J.C.V. Limón; J.F.E. Penagos; U. De Giorgi; K.M. da Trindade; C. Niu; Y. Liu; C.H. Poehlein; J.M. Piulats
errShare
errSave
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study
errFUTURE ONCOLOGY
IF2.6
err2025-05-07
err0
errOAAI
errOzguroglu, Mustafa; Goldman, Jonathan W.; Chen, Yuanbin; Garassino, Marina Chiara; Medic, Nenad; Mann, Helen; Chugh, Priti; Dalvi, Tapashi; Paz-Ares, Luis
errShare
errSave
Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium
errTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
err2025-04-24
err0
errOAAI
errMusa Barış Aykan; Hatice Bölek; Emre Yekedüz; Elif Sertesen; Deniz Tural; Cengiz Karaçin; Mehmet Ali Nahit Şendur; Gökhan Uçar; Çağatay Arslan; Selver Işık; Saadet Sim; Özlem Nuray Sever; Bekir Hacıoğlu; Sema Sezgin Göksu; Mustafa Özgüroğlu; Nuri Karadurmuş; Yüksel Ürün
errShare
errSave
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
errJournal of Thoracic Oncology
IF20.8
err2025-03-19
err0
errOAAI
errSaadettin Kilickap; Ana Baramidze; Ahmet Sezer; Mustafa Özgüroğlu; Mahmut Gumus; Igor Bondarenko; Miranda Gogishvili; Marina Nechaeva; Michael Schenker; Irfan Cicin; Ho Gwo Fuang; Yaroslav Kulyaba; Kasimova Zyuhal; Roxana-Ioana Scheusan; Marina Chiara Garassino; Yuntong Li; Cong Zhu; Manika Kaul; Javier Perez; Frank Seebach; Heather Magnan
errShare
errSave
Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors
errSCIENTIFIC REPORTS
IF3.9
err2025-02-21
err0
errOAAI
errSen, Gulin Alkan; Oztas, Nihan Senturk; Degerli, Ezgi; Safarov, Shamkhal; Guliyev, Murad; Bedir, Sahin; Can, Gunay; Turna, Hande; Ozguroglu, Mustafa
errShare
errSave
Osimertinib after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC): Post-progression outcomes from the phase III LAURA study
errANNALS OF ONCOLOGY
IF65.4
err2024-12-01
err0
PREAI
errOzguroglu, M.; Ahn, M-J.; Dong, X.; Yang, J. C-H.; Oizumi, S.; Goto, K.; Cobo Dols, M.; Kim, S-W.; Hsia, T-C.; Chindaprasirt, J.; Fujiki, F. K.; Valdiviezo, N.; Poole, L.; Evans, A. L.; Armenteros Monterroso, E.; Lu, S.
errShare
errSave
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial
errEUROPEAN UROLOGY ONCOLOGY
IF9.3
err2024-12-01
err2
errOAAI
errSaad, Fred; Armstrong, Andrew J.; Oya, Mototsugu; Vianna, Karina; Ozguroglu, Mustafa; Gedye, Craig; Buchschacher Jr, Gary L.; Lee, Ji Youl; Emmenegger, Urban; Navratil, Jiri; Virizuela, Juan Antonio; Salazar, Anibal; Maillet, Denis; Uemura, Hiroji; Kim, Jeri; Oscroft, Emma; Barker, Laura; Degboe, Arnold; Clarke, Noel W.
errShare
errSave
Outcomes of patients (pts) with unfavourable, nonsquamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errBochtler, T.; Kraemer, A.; Pauli, C.; Duran-Pacheco, G.; Arslan, C.; Bigot, F.; Chalabi, N.; Cook, N.; Italiano, A.; Losa, F.; Menezes, J.; Ma, N.; Ozguroglu, M.; Pazo Cid, R. A.; Ross, J. S.; Shiu, K-K.; Arni, P.; Moch, H.; Mileshkin, L.
errShare
errSave
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
errNEW ENGLAND JOURNAL OF MEDICINE
IF78.5
err2024-08-15
err32
PREAI
errLu, Shun; Kato, Terufumi; Dong, Xiaorong; Ahn, Myung-Ju; Quang, Le-Van; Soparattanapaisarn, Nopadol; Inoue, Takako; Wang, Chih-Liang; Huang, Meijuan; Yang, James Chih-Hsin; Cobo, Manuel; Ozguroglu, Mustafa; Casarini, Ignacio; Khiem, Dang-Van; Sriuranpong, Virote; Cronemberger, Eduardo; Takahashi, Toshiaki; Runglodvatana, Yotsawaj; Chen, Ming; Huang, Xiangning; Grainger, Ellie; Ghiorghiu, Dana; van der Gronde, Toon; Ramalingam, Suresh S.
errShare
errSave
Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer
errJCO GLOBAL ONCOLOGY
IF3
err2024-08-01
err1
errOAAI
errBolek, Hatice; Arslan, Cagatay; Basaran, Mert; Cicin, Irfan; Ozguroglu, Mustafa; Tural, Deniz; Urun, Yuksel
errShare
errSave
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
errLANCET
IF88.5
err2024-08-01
err8
PREAI
errKraemer, Alwin; Bochtler, Tilmann; Pauli, Chantal; Shiu, Kai-Keen; Cook, Natalie; de Menezes, Juliana Janoski; Pazo-Cid, Roberto A.; Losa, Ferran; Robbrecht, Debbie G. J.; Tomasek, Jiri; Arslan, Cagatay; Ozguroglu, Mustafa; Stahl, Michael; Bigot, Frederic; Kim, Sun Young; Naito, Yoichi; Italiano, Antoine; Chalabi, Nassera; Duran-Pacheco, Gonzalo; Michaud, Chantal; Scarato, Jeremy; Thomas, Marlene; Ross, Jeffrey S.; Moch, Holger; Mileshkin, Linda
errShare
errSave
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
errJTO CLINICAL AND RESEARCH REPORTS
IF3.5
err2024-03-01
err3
errOAAI
errVansteenkiste, Johan F.; Naidoo, Jarushka; Faivre-Finn, Corinne; Ozguroglu, Mustafa; Villegas, Augusto; Daniel, Davey; Murakami, Shuji; Hui, Rina; Lee, Ki Hyeong; Cho, Byoung Chul; Kubota, Kaoru; Broadhurst, Helen; Wadsworth, Catherine; Newton, Michael; Thiyagarajah, Piruntha; Antonia, Scott J.
errShare
errSave
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
errANNALS OF ONCOLOGY
IF65.4
err2024-01-01
err32
PREAI
errSiefker-Radtke, A. O.; Matsubara, N.; Park, S. H.; Huddart, R. A.; Burgess, E. F.; Ozguroglu, M.; Valderrama, B. P.; Laguerre, B.; Basso, U.; Triantos, S.; Akapame, S.; Kean, Y.; Deprince, K.; Mukhopadhyay, S.; Loriot, Y.
errShare
errSave
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study
errFUTURE ONCOLOGY
IF2.6
err2023-12-21
err0
errOAAI
errChowdhury, Simon; Bjartell, Anders; Agarwal, Neeraj; Chung, Byung H.; Given, Robert W.; Gomes, Andrea J. Pereira de Santana; Merseburger, Axel S.; Ozguroglu, Mustafa; Soto, Alvaro Juarez; Uemura, Hirotsugu; Ye, Ding-Wei; Brookman-May, Sabine D.; Londhe, Anil; Bhaumik, Amitabha; Mundle, Suneel D.; Larsen, Julie S.; McCarthy, Sharon A.; Chi, Kim N.
errShare
errSave
Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)
errANNALS OF ONCOLOGY
IF65.4
err2023-10-01
err11
errOAAI
errMileshkin, L.; Bochtler, T.; Pauli, C.; Duran-Pacheco, G.; Arslan, C.; Bigot, F.; Chalabi, N.; Cook, N.; Italiano, A.; Losa, F.; Menezes, J.; Michaud, C.; Ozguroglu, M.; Cid, R. A. Pazo; Ross, J. S.; Shiu, K. K.; Stahl, M.; Thomas, M.; Moch, H.; Kraemer, A.
errShare
errSave
Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)
errANNALS OF ONCOLOGY
IF65.4
err2023-10-01
err1
errOAAI
errSiefker-Radtke, A. O.; Matsubara, N.; Park, S. H.; Huddart, R. A.; Burgess, E. F.; Ozguroglu, M.; Perez Valderrama, B.; Triantos, S.; Akapame, S.; Kean, Y.; Deprince, K.; Mukhopadhyay, S.; Loriot, Y.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
E
Eric Van Cutsem
H-index: 174 · Papers: 1.8K
C
Charles S. Fuchs
H-index: 171 · Papers: 1.7K
J
Johann S. de Bono
H-index: 160 · Papers: 2.5K
F
Fabrice André
H-index: 148 · Papers: 1.8K
Y
Yi‐Long Wu
H-index: 135 · Papers: 2.2K
View more